OmniAb Presents New Scientific Data On Its OmnidAb Platform At The 2023 Antibody Engineering & Therapeutics Conference
Portfolio Pulse from Benzinga Newsdesk
OmniAb, Inc. (NASDAQ:OABI) presented new scientific data on its OmnidAb platform at the 2023 Antibody Engineering & Therapeutics Conference. OmnidAb is the first transgenic chicken producing single-domain antibodies (sdAbs), which have broad clinical applications. The company highlighted the platform's benefits, including its optimized human scaffold and efficient in vivo affinity maturation, which minimizes downstream engineering. OmniAb is already working with partners using OmnidAb and introduced its OmniDeep suite of in silico tools for antibody discovery.
December 14, 2023 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OmniAb introduced its OmnidAb platform and OmniDeep tools at a major conference, emphasizing the unique capabilities and potential applications of its transgenic chicken-produced sdAbs.
The presentation of new scientific data and the introduction of the OmnidAb platform at a significant industry conference could generate interest from potential partners and customers, likely leading to positive sentiment in the short term. The uniqueness of the platform and its potential applications in various therapeutic modalities may be seen as a strong competitive advantage, potentially increasing investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100